<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386252</url>
  </required_header>
  <id_info>
    <org_study_id>CL-COV-P01-US</org_study_id>
    <nct_id>NCT04386252</nct_id>
  </id_info>
  <brief_title>Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults</brief_title>
  <official_title>Adaptive Phase IB-II Randomized Clinical Trial Of Preventive Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Subjects Negative For COVID-19 Infection And Anti-SARS-CoV-2 Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aivita Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aivita Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive Phase IB-II trial of a vaccine consisting of autologous dendritic cells
      loaded with antigens from SARS-CoV-2, with or without GM-CSF, to prevent COVID-19 in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects eligible for treatment will be those who are not actively infected with SARS-CoV-2,
      have no evidence of prior infection with SARS-CoV-2 based on serologic testing, and give
      informed consent for vaccination with AV-COVID-19.

      After enrolling, subjects will provide 5 mL of serum from which a rapid test for
      anti-coronavirus antibodies will be performed, and 50 mL of heparinized blood from which
      peripheral blood monocytes will be isolated and differentiated into DC during 5 days of in
      vitro culture with IL-4 and GM-CSF. The autologous DC will then be incubated for 2 days with
      SARS-CoV-2 antigens. Safety and quality testing will be performed on a small quantity of the
      batch, and the remaining DCV will be cryopreserved for shipping to the treatment site.

      Once the Study Drug is ready, the subject will be seen at Study Week-0 for treatment. Prior
      to injection of the Study Drug, 5 mL of blood will be drawn to determine baseline levels of
      anti-SARS-CoV-2 antibodies. At the treatment site, the product will be thawed and admixed
      with either saline or GM-CSF, and within 5 hours of thawing, will be injected s.c. via
      25-gauge needle and 3.0 mL syringe.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm safety</measure>
    <time_frame>6 months</time_frame>
    <description>Confirm safety of AV-COVID-19 by adverse event monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suggestion of efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of IgG and IgM in subject blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal dose of SARS-CoV-2 antigen</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of IgG and IgM in subject blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advantage of administering vaccine admixed with GM-CSF</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of IgG and IgM in subject blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of IgG and IgM in subject blood</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>1x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 1x antigen and admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 1x antigen and admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1x antigen and no GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 1x antigen in saline alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.33x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 3.33x antigen and admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.33x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 3.33x antigen and admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.33x antigen and no GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 3.33x antigen in saline alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 10x antigen and admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 10x antigen and admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10x antigen and no GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-COVID-19 consisting of autologous DC loaded with 10x antigen in saline alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV-COVID-19</intervention_name>
    <description>Autologous dendritic cells loaded with SARS-CoV-2 antigens</description>
    <arm_group_label>10x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>10x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>10x antigen and no GM-CSF</arm_group_label>
    <arm_group_label>1x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>1x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>1x antigen and no GM-CSF</arm_group_label>
    <arm_group_label>3.33x antigen and 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>3.33x antigen and 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>3.33x antigen and no GM-CSF</arm_group_label>
    <other_name>DC-ATA, DCV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older, ECOG 0 or 1

        Exclusion Criteria:

          -  Active COVID-19 infection by PCR testing, Pre-existing IgG or IgM SARS-CoV-2
             antibodies, Pregnant, Known hypersensitivity to GM-CSF, Known active immune deficiency
             disease or active HIV, HBV, HCV, On active treatment with corticosteroids or other
             immunosupressive agent, Participated in previous COVID-19 vaccine study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O Dillman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AIVITA Biomedical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candace Hsieh, PhD</last_name>
    <phone>949-872-2555</phone>
    <phone_ext>110</phone_ext>
    <email>candace@aivitabiomedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Clinical Trials Office - Hoag Cancer Center</last_name>
    </contact>
    <investigator>
      <last_name>Philip Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

